Press releases

  • 2019
  • 2019-07-18 Interim Report January-June 2019
  • 2019-07-16 Ra Pharmaceuticals and Camurus Announce Exclusive License Agreement for FluidCrystal® Extended Release Formulation of Zilucoplan
  • 2019-06-20 Camurus receives IND acceptance from the FDA to enter Phase 3 with CAM2029 for treatment of acromegaly
  • 2019-06-04 Camurus announces publication of Phase 3 study results showing long-term safety, efficacy and high rates of patient satisfaction with Buvidal®
  • 2019-05-09 Resolutions at the annual general meeting 2019 in Camurus
  • 2019-05-09 Camurus Interim Report January-March 2019
  • 2019-05-07 Camurus to present Interim report January-March 2019 on 9 May
  • 2019-04-15 Camurus Annual Report for 2018
  • 2019-04-09 Braeburn initiates court proceedings to overturn exclusivity and seeks immediate market approval of Brixadi™ in the US
  • 2019-04-06 Positive treatment results for Buvidal® in fentanyl users presented at the ASAM 50th Annual Conference
  • 2019-04-05 Notice of annual general meeting 2019 in Camurus AB (publ)
  • 2019-03-29 Change in number of shares and votes in Camurus
  • 2019-03-27 Camurus’ rights issue oversubscribed
  • 2019-03-26 New date for publication of Camurus’ Annual Report 2018
  • 2019-03-08 Camurus publishes prospectus relating to the rights issue
  • 2019-03-05 Resolutions at the Extraordinary General Meeting in Camurus
  • 2019-02-28 Camurus announces the terms of its rights issue
  • 2019-02-14 Camurus to present at the Cowen and Company Annual Healthcare Conference 2019
  • 2019-02-06 Full year report 2018
  • 2019-02-06 Notice of extraordinary general meeting in Camurus AB (publ)
  • 2019-02-06 Camurus to progress commercialization of Buvidal and advance pipeline programs through a fully underwritten rights issue of SEK 400 million
  • 2019-02-01 Camurus to present full year 2018 results on 6 February
  • 2019-01-18 Camurus to present at SEB Biotech Seminar in Stockholm
  • 2019-01-11 Buvidal® launched as the first long-acting opioid dependence treatment in the EU
  •  
  • 2018
  • 2018-12-23 US FDA issues a tentative approval of Brixadi™ (buprenorphine) extended-release injection for treatment of opioid use disorder
  • 2018-12-11 Camurus Capital Markets and R&D Day 11 December 2018
  • 2018-11-28 Buvidal® Weekly and Buvidal® Monthly (CAM2038) approved in Australia as the first long-acting treatment of opioid dependence
  • 2018-11-28 Program for Camurus Capital Markets and R&D Day 11 December 2018
  • 2018-11-22 Camurus receives EU approval for weekly and monthly Buvidal® (CAM2038) for opioid dependence
  • 2018-10-25 Interim Report January-September 2018
  • 2018-10-16 Camurus’ Nomination Committee appointed for the Annual General Meeting 2019
  • 2018-10-10 Camurus to present at Jefferies 2018 London Healthcare Conference
  • 2018-10-09 Save the date: Camurus Capital Markets and R&D Day 11 December 2018
  • 2018-09-21 CHMP recommends approval of Buvidal® (CAM2038) for the treatment of opioid dependence
  • 2018-09-18 Camurus announces positive topline Phase 3 results for CAM2038 in opioid experienced patients with chronic low-back pain
  • 2018-07-17 Interim Report January-June 2018
  • 2018-07-16 Camurus announces PDUFA date for CAM2038 for the treatment of opioid use disorder
  • 2018-06-29 Change in the number of shares and votes in Camurus AB
  • 2018-06-29 Camurus has completed a directed share issue of 1.1 million shares, raising proceeds of approximately SEK 102 million
  • 2018-06-28 Camurus updates its investor relations website
  • 2018-06-28 Camurus intends to launch a directed share issue of approx. MSEK 100
  • 2018-06-12 Camurus and Medison enter into commercialization agreement for CAM2038 in Israel
  • 2018-05-31 Camurus announces positive topline results from Phase 1 study of long-acting treprostinil for the treatment of pulmonary arterial hypertension
  • 2018-05-28 Camurus announces NDA resubmission of weekly and monthly buprenorphine depots to FDA
  • 2018-05-25 Camurus to present at the Jefferies 2018 Global Healthcare Conference
  • 2018-05-14 JAMA Internal Medicine publishes positive Phase 3 pivotal study results for Camurus’ long-acting buprenorphine depots for opioid use disorder
  • 2018-05-03 Resolutions at the annual general meeting 2018 in Camurus
  • 2018-05-03 Interim Report January-March 2018
  • 2018-05-03 Camurus regains worldwide development and commercialization rights to CAM2029 and related product candidates
  • 2018-03-23 Notice of annual general meeting 2018 in Camurus AB (publ)
  • 2018-03-22 Camurus Annual Report for 2017
  • 2018-03-08 Camurus to present at the Cowen and Company Annual Healthcare Conference 2018
  • 2018-02-15 Full year report 2017
  • 2018-01-21 FDA issues complete response letter for CAM2038 for opioid use disorder
  •  
  • 2017
  • 2017-12-21 First cohort dosed in Phase 1 clinical study of sustained release treprostinil injection for treatment of PAH
  • 2017-11-07 Camurus to present at Jefferies 2017 London Healthcare Conference
  • 2017-11-01 Camurus announces that FDA advisory committee recommends approval of CAM2038 for treatment of opioid use disorder
  • 2017-10-30 Camurus announces that FDA has posted briefing material for CAM2038 Advisory Committee meeting
  • 2017-10-26 Interim Report January-September 2017
  • 2017-10-20 Nomination Committee appointed in respect of AGM 2018 in Camurus
  • 2017-09-29 Camurus announces European Medicines Agency validation of CAM2038 Marketing Authorization Application for treatment of opioid dependence
  • 2017-09-18 Camurus Announces that FDA Grants Priority Review of NDA for Weekly and Monthly CAM2038 Buprenorphine Depots for Treatment of Opioid Use Disorder
  • 2017-07-20 Camurus and Braeburn Announce Submission of NDA for Long-Acting Buprenorphine (CAM2038) for Opioid Use Disorder
  • 2017-07-13 Interim report January-June 2017
  • 2017-07-12 Camurus and Braeburn Pharmaceuticals Announce Topline Phase 2 Results for Long-acting Buprenorphine in Opioid Dependent Patients with Chronic Pain
  • 2017-06-27 Rhythm and Camurus Announce Positive Initial Data for Extended-Release Delivery of Setmelanotide for Treatment of Rare Genetic Disorders of Obesity
  • 2017-06-22 Long-acting Buprenorphine Blocks Opioid Effects and Suppresses Withdrawal Symptoms in Adults with Opioid Use Disorder
  • 2017-06-15 Camurus and Braeburn Pharmaceuticals Announce Presentations of Pivotal Clinical Study Data of Long-acting Buprenorphine
  • 2017-05-03 Resolutions at the annual general meeting 2017 in Camurus
  • 2017-05-03 Interim Report January-March 2017
  • 2017-05-02 Camurus and Braeburn Pharmaceuticals Announce Positive Top-line Results from Long-term Phase 3 Safety Study of CAM2038
  • 2017-03-31 Camurus appoints VP Corporate Development & General Counsel
  • 2017-03-30 Camurus Annual Report for 2016 released
  • 2017-03-30 Notice of annual general meeting 2017 in Camurus AB (publ)
  • 2017-03-09 Ethypharm and Camurus sign agreement for distribution of episil® in France
  • 2017-02-16 Full year report 2016
  • 2017-02-02 Camurus to present at the Cowen and Company Annual Healthcare Conference 2017
  • 2017-01-09 Camurus to present at the J.P. Morgan Annual Healthcare Conference 2017
  •  
  • 2016
  • 2016-12-14 Camurus Capital Markets and R&D Day 2016
  • 2016-11-25 Program for Camurus’ Capital Markets and R&D Day 14 December 2016
  • 2016-11-14 Braeburn Pharmaceuticals and Camurus Announce Positive Top-line Phase 3 Results for Long-acting Buprenorphine for Treatment of Opioid Addiction
  • 2016-11-11 Camurus to provide an update on the progress of its research and development programs at the Jefferies 2016 Healthcare Conference
  • 2016-11-08 Interim report January-September 2016
  • 2016-11-01 Camurus to host a Capital Markets Day 14 December 2016
  • 2016-10-28 Nomination Committee appointed in respect of AGM 2017 in Camurus
  • 2016-10-24 Braeburn Pharmaceuticals and Camurus Expand Collaboration and License Agreement to include New Combination Product for Pain and Nausea
  • 2016-10-21 Braeburn Pharmaceuticals and Camurus announce the presentation of new data from clinical studies of long-acting buprenorphine
  • 2016-09-30 Braeburn Pharmaceuticals and Camurus Enroll First Patients in a Phase 3 Efficacy Trial of CAM2038 for treatment of Chronic Low Back Pain
  • 2016-07-14 Interim report January-June 2016
  • 2016-07-12 Camurus announces completion of Phase 2 study of CAM2029 in patients with acromegaly and neuroendocrine tumors
  • 2016-06-21 Camurus announces results from a Phase 2 trial of CAM2032 in patients with prostate cancer
  • 2016-06-20 Richard Jameson assumes position as Camurus’ Chief Commercial Officer
  • 2016-05-17 Camurus Interim Report January-March 2016
  • 2016-05-11 Braeburn Pharmaceuticals and Camurus announce positive results from Phase 2 opioid challenge study with CAM2038 in subjects with opioid use disorder
  • 2016-05-03 Resolutions at the Annual General Meeting 2016 in Camurus
  • 2016-04-21 Distribution agreement signed with R-PHARM US for episil®
  • 2016-04-05 Braeburn Pharmaceuticals and Camurus announce Enrollment goals reached in two pivotal Phase 3 Trials of CAM2038 for treatment of opioid dependence
  • 2016-03-30 Notice of annual general meeting 2016 and proposal for new incentive program in Camurus AB (publ)
  • 2016-03-30 Camurus Annual Report for 2015 released
  • 2016-02-22 Braeburn and Camurus Announce Initiation of a Phase 2 Study in Opioid Dependent Patients with Moderate to Severe Chronic Pain